Search Results
Aug 18, 2025, 17:00 ET REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
AAV therapeutic for the treatment of boys with MPS II, designed to deliver the iduronate-2-sulfatase (IDS) gene to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the
More news about: REGENXBIO Inc.
Aug 18, 2025, 09:29 ET Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers
collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a
More news about: Genprex, Inc.
Aug 18, 2025, 08:45 ET The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders
during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: The Gross Law Firm
Aug 18, 2025, 08:30 ET High-Titer Lentivirus Solutions in 5 Days: Break Production Barriers for CGT, Upcoming Webinar Hosted by Xtalks
indispensable tools in cell and gene therapy (CGT) research, due to their ability to stably integrate genetic material into both dividing and non-dividing cells. Their versatility makes them particularly well-suited for delivering a wide range of payloads — from classical gene addition constructs to complex
More news about: Xtalks
Aug 18, 2025, 08:30 ET Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market
(NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and
More news about: Klotho Neurosciences, Inc.
Aug 18, 2025, 08:30 ET Unlocking Oncology Pipelines with Next-Gen AI and Functional Data, Upcoming Webinar Hosted by Xtalks
to uncover and validate a novel oncology target: Vacuolar Protein Sorting–associated protein 4 (VPS4A/B). The discovery process began with a gene knockdown screen performed in 3D ex vivo cultures derived from clinically annotated patient-derived xenograft (PDX) tumors. Functional outcomes
More news about: Xtalks
Aug 17, 2025, 08:01 ET GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation
Highlights: Innovation and Gene-to-Protein Platform Excellence The Life Science Services and Products segment generated US$247.6 million in revenue (+11.3% YoY), powered by breakthrough increases in gene synthesis throughput. The protein business
More news about: GenScript Biotech Corporation
Aug 15, 2025, 11:00 ET Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR | MarketsandMarkets™
antibodies for the detection, identification, and modification of proteins, along with their essential function in monitoring cellular regulation and gene expression. Consequently, the growth of the antibodies segment is expected to accelerate throughout the forecast period due to these advancements.
More news about: MarketsandMarkets
Aug 15, 2025, 10:49 ET Children's Hospital of Philadelphia Researchers Find that Missing Messenger RNA Fragments Could be Key to New Immunotherapy for Hard-to-Treat Tumors
unacceptable. This means that deep knowledge of gene expression patterns exclusive to tumor cells is critical. A potential means of discovering new therapeutic targets for brain tumors may lie in alternative splicing, a process whereby a single gene produces multiple proteins by rearranging exons,
More news about: Children's Hospital of Philadelphia
Aug 15, 2025, 09:15 ET Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: Levi & Korsinsky, LLP
Aug 15, 2025, 08:30 ET Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek®
George W. Sledge, Jr., MD, Caris EVP and Chief Medical Officer. "By integrating companion diagnostic tests into multi-gene panels that make the most of tissue samples, we can reduce inefficiencies and potentially help more patients access personalized therapies." MI
More news about: Caris Life Sciences
Aug 15, 2025, 07:00 ET Novel Gene Therapy for ALS cleared for global trials in China and the U.S.
advancing its first-in-class gene therapy to address the unmet and urgent needs of the global ALS community. About SNUG01 SNUG01, developed by SineuGene via its proprietary AAV technology platform, is a first-in-class gene therapy product using TRIM72 as the gene of interest. TRIM72 was
More news about: SineuGene Therapeutics
Aug 15, 2025, 06:42 ET Weekly Recap: 14 Health Press Releases You Need to See
ProBio Launches GMP AAV Manufacturing Services at Hopewell Facility to Advance Gene Therapy Development and Manufacturing ProBio's new capabilities offer clients fully integrated services—including GMP plasmid DNA production,
More news about: PR Newswire
Aug 14, 2025, 17:56 ET Advocate Health's unwavering commitment to rural community health care highlighted in new report
"Access to nation-leading care shouldn't depend on your ZIP code or size of your town" - Gene Woods, CEO Advocate HealthThe white paper, published this week at
More news about: ATRIUM HEALTH
Aug 14, 2025, 17:46 ET Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight
which uses surgical findings (Stages I–IV, 4S). Risk assessment under the INRG framework incorporates both clinical and genetic factors, such as MYCN gene amplification, chromosome 11q status, and tumor cell ploidy, to categorize tumors into very low-, low-, intermediate-, or high-risk groups. Pediatric
More news about: DelveInsight Business Research, LLP
Aug 14, 2025, 16:05 ET Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
potency against activating FGFR2 gene alterations and resistance mutations. The SURF201 study continues to enroll and dose adults with unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors with activating FGFR2 gene alterations.SNÅP Platform
More news about: Tyra Biosciences
Aug 14, 2025, 15:13 ET Emmaus Life Sciences Reports Quarterly Financial Results
DiseaseThere are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally. The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an estimated 1-in-365 African Americans and 1-in-16,300
More news about: Emmaus Life Sciences, Inc.
Aug 14, 2025, 09:20 ET Made Scientific and New Jersey Delegates Celebrate Grand Opening of Flagship Cell Therapy Manufacturing Facility
region, underscoring New Jersey's role in the growing national landscape of advanced biomanufacturing and cell and gene therapy innovation.
More news about: Made Scientific, Inc.
Aug 14, 2025, 08:45 ET Investors in Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights - SRPT
during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: The Gross Law Firm
Aug 14, 2025, 08:36 ET Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering vision loss from retinal degenerative diseases, today announced the publication of positive results from its
More news about: Nanoscope Therapeutics
Aug 14, 2025, 07:02 ET BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn for the upcoming Phase 3b clinical trial.NurOwn® data selected as Breakthrough
More news about: BrainStorm Cell Therapeutics Inc.
Aug 14, 2025, 07:00 ET ScaleReady Announces Award of a G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory
supports researchers and clinicians who specialize in regenerative, cell and gene therapies, accelerating their discoveries from concepts to cures. About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform
More news about: Bio-Techne Corporation
Aug 14, 2025, 07:00 ET BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
combination.Sickle Cell Disease (SCD) & Gene Therapy Ongoing Phase 1 clinical trial evaluating motixafortide as monotherapy and in combination with natalizumab for stem cell mobilization for gene therapies in sickle cell disease continues to progress. The
More news about: BioLineRx Ltd.
Aug 13, 2025, 16:05 ET Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Pipeline Updates ELVN-001 is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). In June 2025,
More news about: Enliven Therapeutics, Inc.
Aug 13, 2025, 11:12 ET 'Functional Unemployment' Rises; Black, Hispanic Workers Take Biggest Hit, Says Ludwig Institute
@LISEP_org. About Gene LudwigIn addition to his role as LISEP chair, Gene Ludwig is a managing partner of Canapi LLC, a financial technology venture fund. He is the founder
More news about: Ludwig Institute for Shared Economic Prosperity